Announcements Trials
Browse Landscape

Phase

Phase 1/2 4Phase EARLY_PHASE1 1

Status

Recruiting 3Completed 1Active not recruiting 1

Sponsor Class

INDUSTRY 4OTHER 1

Study Type

Interventional 5

Sponsor

Cancer Type

Lymphoid 5Dermatologic 3Head & Neck 2Sarcoma 1Breast 1

Conditions

Carcinoma, Non-Small-Cell Lung 59Parkinson Disease 4, Autosomal Dominant Lewy Body 25Lung Neoplasms 25Squamous Cell Carcinoma of Head and Neck 20Melanoma 19Neoplasm Metastasis 18Neoplasms 16Endometrial Neoplasms 14Colorectal Neoplasms 14Breast Neoplasms 14Triple Negative Breast Neoplasms 12Ovarian Neoplasms 11Head and Neck Neoplasms 9Carcinoma, Renal Cell 8Pancreatic Neoplasms 7Carcinoma, Transitional Cell 7Urinary Bladder Neoplasms 6Recurrence 5Lymphoma 5Hodgkin Disease 5Esophageal Neoplasms 4Carcinoma 4Brain Neoplasms 4Uterine Cervical Neoplasms 3Stomach Neoplasms 3Small Cell Lung Carcinoma 3Sarcoma 3Prostatic Neoplasms 3Lymphoma, Large B-Cell, Diffuse 3Fallopian Tube Neoplasms 3

Interventions

Rituximab 12Biopsy 12Specimen Handling 11Cyclophosphamide 11Magnetic Resonance Spectroscopy 10obinutuzumab 7Lenalidomide 7fludarabine 6Prednisone 6pembrolizumab 5Nuclear Medicine Department, Hospital 5X-Rays 4Doxorubicin 4venetoclax 3ibrutinib 3glofitamab 3fludarabine phosphate 3acalabrutinib 3Vincristine 3Tacrolimus 3Mycophenolic Acid 3GSK2636771 3Etoposide 3Busulfan 3Bendamustine Hydrochloride 3zanubrutinib 2trametinib 2tocilizumab 2palbociclib 2osimertinib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Lymphoma × pembrolizumab × 30 days × Clear all
NCT07302347 2026-06-05

MK-3475-G21

Merck Sharp & Dohme LLC

Phase 1/2 Recruiting
20 enrolled
DermatologicLymphoid

Lymphoma, Neoplasms, Carcinoma, Merkel Cell

NCT02332668 2026-06-01

MK-3475-051

Merck Sharp & Dohme LLC

Phase 1/2 Recruiting
370 enrolled
DermatologicLymphoid

Lymphoma, Melanoma

NCT03789097 2026-05-22

Vaccination With Flt3L, Radiation, and Poly-ICLC

Icahn School of Medicine at Mount Sinai

Phase 1/2 Completed
17 enrolled
BreastHead & NeckLymphoid

Squamous Cell Carcinoma of Head and Neck, Breast Neoplasms, Carcinoma, Lymphoma, Lymphoma, Non-Hodgkin

NCT04541108 2026-05-22

Phase 0 Master Protocol for CIVO Intratumoral Microdosing of Anti-Cancer Therapies

Presage Biosciences

Phase EARLY_PHASE1 Active not recruiting
15 enrolled
DermatologicHead & NeckLymphoidSarcoma

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms, Lymphoma, Melanoma, Sarcoma

NCT06137144 2026-05-19

PRIMAVERA

AstraZeneca

Phase 1/2 Recruiting
161 enrolled
Lymphoid

Hodgkin Disease, Lymphoma, Lymphoma, Non-Hodgkin, Lymphoma, T-Cell, Peripheral

Data powered by HemOnc (CC BY 4.0) Colophon âš¡